FDA Product Code DAP: Fibrinogen And Fibrin Split Products, Antigen, Antiserum, Control
Under FDA product code DAP, fibrinogen and fibrin split product antigen/antibody detection systems are cleared for the evaluation of coagulation disorders.
These tests measure fibrin degradation products and D-dimer in plasma to detect excessive fibrinolysis, disseminated intravascular coagulation, and venous thromboembolism. Elevated FDP and D-dimer indicate ongoing coagulation and fibrinolysis activity.
DAP devices are Class II medical devices, regulated under 21 CFR 864.7320 and reviewed by the FDA Hematology panel.
Leading manufacturers include Instrumentation Laboratory CO, Dade Behring, Inc. and Organon Teknika Corp..
FDA 510(k) Cleared Fibrinogen And Fibrin Split Products, Antigen, Antiserum, Control Devices (Product Code DAP)
About Product Code DAP - Regulatory Context
510(k) Submission Activity
58 total 510(k) submissions under product code DAP since 1986, with 58 receiving FDA clearance (average review time: 139 days).
Submission volume has increased in recent years - 1 submissions in the last 24 months compared to 0 in the prior period - suggesting growing market activity in this device classification.
FDA 510(k) Review Time - DAP Product Code
Recent submissions under DAP have taken an average of 242 days to reach a decision - up from 137 days historically. Manufacturers should account for longer review timelines in current project planning.
DAP devices are reviewed by the Hematology panel. Browse all Hematology devices →